Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 9:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Ventral Hernia Repair
Interventions: Gemcitabine/ clindamycin, Normal saline; Drug
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Parkinson Disease, Depression
Interventions: OnabotulinumtoxinA, Control; Biological
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cerebral Palsy, Hip Dysplasia, Pain, Postoperative
Interventions: Ropivacaine injection, normal saline; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Up to 18 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Los Angeles, California • Santa Monica, California • Chicago, Illinois

Conditions: Lumbar; Injury
Interventions: Acetaminophen, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease
Interventions: L-citrulline, Placebo; Drug · Other
Lead sponsor: Asklepion Pharmaceuticals, LLC; Industry
Eligibility: 6 Years to 21 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Coral Gables, Florida • Atlanta, Georgia + 3 more

Conditions: Surgery, Sedation
Interventions: Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infections
Interventions: E-101 Solution 300 GU/ml, Saline solution; Drug
Lead sponsor: Excited States, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 34
States / cities: Mobile, Alabama • Los Angeles, California • Stanford, California + 29 more

Conditions: Immunization; Infection, Transplantation Infection, Influenza
Interventions: High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 16 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cystic Fibrosis
Interventions: Gallium nitrate, Normal Saline; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 23
States / cities: Birmingham, Alabama • La Jolla, California • Denver, Colorado + 20 more

Conditions: Reperfusion Injury
Interventions: Ascorbic Acid, 5 % Dextrose Water or Normal Saline; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Vitamin B 12 Deficiency
Interventions: Cyanocobalamin, Placebo; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pregnancy
Interventions: Lidocaine, Normal Saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions: Anakinra, 0.9% Saline; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Clinical Center Reference Endotoxin (CCRE), Normal saline; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: PTSD, Cardiac Arrest, Anxiety and Fear, Sleep Disturbance, Health Behavior
Interventions: stellate ganglion block injection, Normal saline injection, Psychoeducation; Procedure · Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Radiocontrast Nephropathy
Interventions: N-Acetylcysteine (NAC), 0.9% Sodium-chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Dysphagia
Interventions: bupivacaine hydrochloride 0.5% solution, 0.9% NaCl solution; Drug
Lead sponsor: Justin Parker Neurological Institute; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Ductal Carcinoma In Situ
Interventions: Carboplatin i.d. Days 1 & 15, Carboplatin i.d. Day 1; Normal Saline i.d. Day 15, Normal Saline; Drug
Lead sponsor: Windy Hill Medical, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma • Houston, Texas

Conditions: Acute Respiratory Distress Syndrome, Lung Diseases, Pneumonia, Respiratory Tract Infections, Respiratory Tract Disease
Interventions: Siltuximab, Normal Saline; Drug · Other
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Lansing, Michigan • Charlotte, North Carolina

Conditions: Healthy
Interventions: Liposomal Bupivacaine 13.3, Bupivacaine, Placebo; Drug · Other
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ovarian Cancer, Uterine Cancer
Interventions: fosaprepitant, aprepitant, Oral Placebo, IV placebo; Drug · Other
Lead sponsor: Gynecologic Oncology Associates; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Shock,Hemorrhagic
Interventions: Valproic Acid, Isotonic saline solution; Drug
Lead sponsor: Dr. Hasan Alam; Other
Eligibility: 18 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Urinary Bladder Neoplasms
Interventions: Magnetic Resonance Imaging, Gadobutrol intravesical administration (4mM), Ferumoxytol intravesical administration (5 mM); Diagnostic Test · Drug
Lead sponsor: Jodi Maranchie; Other
Eligibility: 18 Years to 90 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Overactive Bladder
Interventions: onabotulinumtoxinA, normal saline; Biological · Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 548 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Laguna Hills, California

Search by objective public record fields.

Reducing INfection at the Surgical SitE With Antibiotic Irrigation During Ventral Hernia Repair (RINSE Trial)

Trial of OnabotulinumtoxinA for Depression in Parkinson Disease

Peri-operative Use of a Pain Injection in Pediatric Patients With Cerebral Palsy

Assessing Efficacy of Intravenous Acetaminophen for Perioperative Pain Treatment in Spinal Surgery

A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

Oral Versus Intravenous Sedation for Ocular Procedures

Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)

Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients

Effects of Vitamin B12 Treatment in Singers

Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery

Anakinra, COVID-19, Cytokine Storm

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

Stellate Ganglion Blockade to Reduce Cardiac Anxiety and PTSD Symptoms in Cardiac Arrest Survivors

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

Anesthetic to Reduce Dysphagia After Anterior Cervical Discectomy and Fusion Surgery

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

SILtuximab in Viral ARds (SILVAR) Study

Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers

Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)

Virtual Histology of the Bladder Wall for Bladder Cancer Staging

Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence